Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity’s rights under its agreements with Cloud Software Group (CSG) related to the Spotfire^® software.

This ruling follows a preliminary injunction issued in April 2024, which will become permanent, ensuring uninterrupted access to Spotfire software and support for Revvity and its customers, protecting operational continuity and service quality.

“We are pleased with the court's decision upholding our agreements and the commitments made to our customers,” said Kevin Willoe, SVP and general manager at Revvity Signals Software. “This ruling reinforces our dedication to delivering the reliable, high-quality service that empowers scientists to drive meaningful discoveries. We look forward to continuing our historically collaborative and productive partnership with CSG as the exclusive provider of Spotfire to the research and clinical markets through 2034 and hopefully beyond.”

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250220424412/en/